

Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial

Supplementary Material

Ning Kong,¹ Yu Xue,¹ Li Mao,² Long Qian,³ Hongtao Guo,⁴ Jiankang Hu,⁵ Fenghong Yuan,⁶ Rongbin Li,⁷ Xinwang Duan,⁸ Jing Yu,⁹ Wei Gou,¹⁰ Lei Yang,¹¹ Hua Wei,¹² Rongping Li,¹³ Qian Xu,¹⁴ Tianhong Luo,¹⁴ Xu Zhang,¹⁴ Hejian Zou¹

¹Department of Rheumatology and Immunology, Huashan Hospital, Fudan University, Shanghai, China; ²Huai'an First People's Hospital, Huai'an, China; ³The Second Hospital of Anhui Medical University, Hefei, China; ⁴The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China; ⁵Pingxiang People's Hospital, Pingxiang, China; ⁶Wuxi People's Hospital, Wuxi, China; ⁷The First Hospital of Qiqihar, Qiqihar, China; ⁸The Second Affiliated Hospital of Nanchang University, Nanchang, China; ⁹The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China; ¹⁰Hebei Petro China Central Hospital, Langfang, China; ¹¹Zhengzhou Central Hospital, Zhengzhou, China; ¹²Northern Jiangsu People's Hospital, Yangzhou, China; ¹³The First Affiliated Hospital of Gannan Medical University, Ganzhou, China; ¹⁴Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China

Corresponding author: Hejian Zou, Huashan Hospital, Fudan University, Shanghai, China; Email: hejian_zou@163.com; ORCID iD: 0000-0001-9762-2663.

Table S1 Participating study sites and ethics committees

Hospital number	Hospital name	Ethics committee name
1	Huashan Hospital, Fudan University	The Ethics Committee of Huashan Hospital, Fudan University
2	The Third People's Hospital of Huzhou	Medical Ethics Committee of The Third People's Hospital of Huzhou
3	Second Affiliated Hospital of Soochow University	Ethics Committee of The Second Affiliated Hospital of Soochow University
4	Huai'an First People's Hospital	Medical Ethics Committee of Huai'an First People's Hospital
5	Northern Jiangsu People's Hospital	Medical Ethics Committee of Northern Jiangsu People's Hospital
6	Wuxi People's Hospital	Ethics Committee of Clinical Trials, Wuxi People's Hospital
7	The Second Hospital of Anhui Medical University	Drug Clinical Trial Ethics Committee of The Second Hospital of Anhui Medical University
8	Zhuzhou Central Hospital	Drug Clinical Trial Ethics Committee of Zhuzhou Central Hospital
9	Xiangtan Central Hospital	Clinical Trial Ethics Committee of Xiangtan Central Hospital
10	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
11	The Affiliated Hospital of Binzhou Medical University	Clinical Trial Ethics Committee of the Affiliated Hospital of Binzhou Medical University
12	Jining No.1 People's Hospital	Ethics Committee of Jining No.1 People's Hospital
13	Linyi People's Hospital	Clinical Trial Ethics Committee of Linyi People's Hospital
14	Shandong Provincial Third Hospital	Ethics Committee of Shandong Provincial Third Hospital
15	The First Hospital of Shanxi Medical University	Ethics Review Committee of Drug/Medical Device Clinical Trials, The First Hospital of Shanxi Medical University
16	Yuncheng Central Hospital	Ethics Committee of Yuncheng Central Hospital, Shanxi Province
17	The First Hospital of Qiqihar	Medical Ethics Committee of The First Hospital of Qiqihar

18	Jilin Provincial People's Hospital	Drug/Device Clinical Trial Ethics Committee of Jilin Provincial People's Hospital
19	The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine	Ethics Committee of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
20	Shengjing Hospital Affiliated to China Medical University	Medical Ethics Committee of Shengjing Hospital Affiliated to China Medical University
21	First Hospital of Hebei Medical University	Drug Clinical Trial Ethics Committee of the First Hospital of Hebei Medical University
22	Hebei Petro China Central Hospital	Clinical Trial Ethics Committee of Hebei Petro China Central Hospital
23	First Affiliated Hospital of Henan University of Science and Technology	Medical Ethics Committee of the First Affiliated Hospital of Henan University of Science and Technology
24	The First Affiliated Hospital of Zhengzhou University	Ethics Committee of Scientific Research and Clinical Trials, the First Affiliated Hospital of Zhengzhou University
25	The First Affiliated Hospital of Henan University of Chinese Medicine	Ethics Committee of the First Affiliated Hospital of Henan University of Chinese Medicine
26	Xinxiang Central Hospital	Ethics Committee of Xinxiang Central Hospital
27	Zhengzhou Central Hospital	Drug Clinical Trial Ethics Committee of Zhengzhou Central Hospital
28	The First Affiliated Hospital of Gannan Medical University	Drug Clinical Trial Ethics Committee of the First Affiliated Hospital of Gannan Medical University
29	Jiangxi Provincial People's Hospital	Medical Ethics Committee of Jiangxi Provincial People's Hospital
30	The Second Affiliated Hospital of Nanchang University	Clinical Trial Ethics Committee of the Second Affiliated Hospital of Nanchang University
31	Pingxiang People's Hospital	Ethics Committee of Pingxiang People's Hospital
32	The First People's Hospital of Yibin	Clinical Trial Ethics Committee of The First People's Hospital of Yibin
33	Mianyang Central Hospital	Clinical Trial Ethics Committee of Mianyang Central Hospital
34	Suining Central Hospital	Clinical Trial Ethics Committee of Suining Central Hospital
35	Zhongshan Hospital of Traditional Chinese Medicine	Ethics Committee of Zhongshan Hospital of Traditional Chinese Medicine

36	The First Affiliated Hospital of Guangxi Medical University	Drug Clinical Trial Ethics Committee of The First Affiliated Hospital of Guangxi Medical University
37	The First Affiliated Hospital of Hainan Medical University	Medical Ethics Committee of The First Affiliated Hospital of Hainan Medical University

Table S2 Summary of ADAs and NAbS by treatment group (ADAS)

	Firsekibart (n=61)	Etoricoxib-to-firsekibart switchers (n=41)
Prior to firsekibart administration		
Total (missing), n	61 (0)	41 (0)
ADA positive	4 (6.6)	1 (2.4)
NAb positive	0	1 (2.4)
Overall results after administration		
Total (missing), n	61 (0)	41 (0)
ADA positive	11 (18.0)	1 (2.4)
NAb positive	0	1 (2.4)
Overall results (pre- and post-dose)		
Total (missing), n	61 (0)	41 (0)
ADA positive	12 (19.7)	1 (2.4)
NAb positive	0	1 (2.4)

Data are n (%), unless otherwise stated.

ADA, anti-drug antibody; ADAS, immunogenicity (ADA) set; NAb, neutralizing antibody.